Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
Leptin and visfatin serum levels in non-diabetic ankylosing spondylitis patients undergoing TNF-α antagonist therapy
Clinical and Experimental Rheumatology, Volume 31, No. 4, Year 2013
Notification
URL copied to clipboard!
Description
Objectives: This paper aims to determine whether disease activity, systemic inflammation and metabolic syndrome are potential determinants of circulating leptin and visfatin levels in ankylosing spondylitis (AS) patients undergoing TNF-α antagonist therapy. We also assessed whether the infusion of infliximab may alter circulating leptin and visfatin concentrations in these patients. Methods: We investigated leptin and visfatin serum concentrations in a series of 30 non-diabetic AS patients without history of cardiovascular (CV) events that were treated with the TNF-α antagonist infliximab, immediately prior to an infliximab infusion. Leptin and visfatin levels were also determined immediately after administration of an infliximab dose. Results: Significant differences in leptin concentrations between men (8.85±5.31 ng/ml) and women (18.96±9.72 ng/ml) were observed (p=0.001). A significant correlation between visfatin concentrations and insulin resistance (HOMA at the time of the study) was found (r= 0.493; p=0.009). Circulating leptin and visfatin concentrations did not correlate with disease duration, erythrocyte sedimentation rate, C-reactive protein, BASDAI and VAS at the time of the study and adiponectin and resistin levels prior to infliximab infusion. Likewise, no differences in leptin and visfatin concentrations were observed when patients with a history of anterior uveitis or presence of syndesmophytes were compared with the remaining patients who did not exhibit these features. Leptin and visfatin levels did not change upon infliximab administration. Conclusion: The present study indicates that in non-diabetic patients with AS on treatment with infliximab leptin and visfatin serum levels do not correlate with disease activity or systemic inflammation. Nevertheless, visfatin concentration correlates with insulin resistance. © Clinical and Experimental Rheumatology 2013.
Authors & Co-Authors
Miranda-Filloy, José Alberto
Spain, Lugo
Complejo Hospitalario Xeral Calde
López-Mejías, Raquel
Unknown Affiliation
Genre, Fernanda
Unknown Affiliation
Carnero-López, Beatriz
Spain, Ponferrada
Hospital el Bierzo
González-Juanatey, Carlos
Spain, Lugo
Complejo Hospitalario Xeral Calde
Blanco-Alonso, Ricardo
Unknown Affiliation
Llorca-Díaz, Javier Francisco
Spain, Madrid
Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública
González-Gay, Miguel Ángel
Unknown Affiliation
Statistics
Citations: 24
Authors: 8
Affiliations: 4
Identifiers
ISSN:
1593098X
Research Areas
Noncommunicable Diseases
Participants Gender
Male
Female